Cor Vasa 2008, 50(6):259-267 | DOI: 10.33678/cor.2008.083

Management of chronic heart failure

Jiří Vítovec1, Jindřich Špinar2
1 I. interní kardioangiologická klinika, Fakultní nemocnice u sv. Anny
2 Interní kardiologická klinika, Fakulní nemocnice Brno, Lékařská fakulta Masarykovy univerzity, Brno, Česká republika

The approach to the patient with cardiac insufficiency has changed markedly over the past decade. Current management is focused not only on modulating symptoms of dyspnea and fatigue but, primarily, on modulating the incidence and progression of heart failure and reducing mortality. Most therapeutic strategies today are based on the results of large randomized studies, which have demonstrated that the therapeutic approach in question is beneficial for the patient, either by extending their lives and/or improving their quality of life. In addition to the impressive advances made in drug therapy, the prognosis of patients has been largely affected by the introduction of cardiac resynchronization therapy and implantable defibrillators into clinical practice. Likewise, patients with heart failure are more often indicated for revascularization procedures; those meeting indication criteria are eligible for treatment using left-heart assist devices, elimination methods and, last but not least, heart transplantation.

Keywords: Heart failure; Drug therapy; Resynchronization therapy; Implantable defibrillators; Elimination methods

Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, Špinar J. Management of chronic heart failure. Cor Vasa. 2008;50(6):259-267. doi: 10.33678/cor.2008.083.
Download citation

References

  1. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417-24.
  2. Anand IS, Florea VG. Diuretics in chronic heart failure - benefits and hazards. Eur Heart J 2001;3 (Suppl G): G8-G18. Go to original source...
  3. Aschermann M a spol. Kardiologie. Praha: Galen, 2004: 1481.
  4. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80. Go to original source...
  5. Baker DW, Jones R, Hodges J, et al. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994;272:1528-34. Go to original source... Go to PubMed...
  6. Baker DW. Prevention of heart failure. J Card Fail 2002;8:333-46. Go to original source... Go to PubMed...
  7. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685-93. Go to original source... Go to PubMed...
  8. Bardy GH, Lee KL, Mark DB, et al. for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. Go to original source... Go to PubMed...
  9. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure. J Am Coll Cardiol 2005;46:2043-6. Go to original source... Go to PubMed...
  10. Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001;85:E8. Go to original source... Go to PubMed...
  11. Bristow MR, Saxon LA, Boehmer J, et al. for COMPANION Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-50. Go to original source... Go to PubMed...
  12. Bytešník J. Doporučené postupy pro diagnostiku a léčbu komorových arytmií. Cor Vasa 2005;47 (Suppl):41-57.
  13. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13. Go to original source...
  14. Cleland JGF, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157-64. Go to original source... Go to PubMed...
  15. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25. Go to original source... Go to PubMed...
  16. Haller Ch. Diuretics in congestive heart failure: new evidence for old problems. Nephrol Dial Transplant 1999;14:1358-60. Go to original source... Go to PubMed...
  17. Hershberger RE, Nauman D, Walker TL, Dutton D, Burgess D. Care Processes and Clinical Outcomes of Continuous Outpatient Support with Inotropes (COSI) in Patients with Refractory Endstage Heart Failure. J Card Fail 2003;9:180-7. Go to original source... Go to PubMed...
  18. Hradec J. Farmakoterapie v kardiologii. V: Marek J a kol. Farmakoterapie vnitřních nemocí. 3. vydání. Praha: Grada Publishing, 2005:25-62.
  19. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guidelines update for the diagnosis and management of chronic heart failure in the adult: summary article: a report from the ACC/AHA. Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evolution and Management of Heart Failure). Circulation 2005;112:1825-52.
  20. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992;70:479-87. Go to original source... Go to PubMed...
  21. López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341-62. Go to original source... Go to PubMed...
  22. Lukl J, Heinc P, a kol. Moderní léčba arytmií. Praha: Grada Publishing, 2001:173-7.
  23. Masoudi FA, Wolfe P, Havranek EP, et al. Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. J Am Coll Cardiol 2005;46:955-62. Go to original source...
  24. Massie BM, Krol WF, Ammon SE, et al. The warfarin and antiplatelet therapy in heart failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004;10:101-12. Go to original source... Go to PubMed...
  25. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7. Go to original source...
  26. Morgan JM. The MADIT II and COMPANION studies: will they affect uptake of device treatment? Heart 2004; 90:243-5. Go to original source... Go to PubMed...
  27. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8. Go to original source... Go to PubMed...
  28. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-8. Go to original source... Go to PubMed...
  29. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. Go to original source... Go to PubMed...
  30. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation. Study Investigators. N Engl J Med 1999;341:709-17. Go to original source... Go to PubMed...
  31. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. Go to original source... Go to PubMed...
  32. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-8. Go to original source... Go to PubMed...
  33. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-11. Go to original source... Go to PubMed...
  34. Remme WJ. Should ACE inhibitors Always be First - Line Therapy in Heart Fauilure? Lessons from the CARMEN Study. Cardiovasc Drugs Ther 2003;17:107-9. Go to original source... Go to PubMed...
  35. Reyes AJ, Taylor SH. Diuretics in Cardiovascular Therapy: The new Clinicopharmacological Bases That Matter. Cardiovasc Drug Ther 1999;13:371-98. Go to original source... Go to PubMed...
  36. Shlipak MG. Pharmacotherapy for Heart Failure in Patients with Renal Insuficiency. Ann Int Med 2003; 138:917-24. Go to original source... Go to PubMed...
  37. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40. Go to original source... Go to PubMed...
  38. Špinar J, Vítovec J. Betablokátory a závažné chronické srdeční selhání. Cor Vasa 2000;42:491-2.
  39. Špinar J, Hradec J, Meluzín J, a spol. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006. Cor Vasa 2007;49:K5-K34.
  40. The Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90. Go to original source... Go to PubMed...
  41. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35. Go to original source... Go to PubMed...
  42. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33. Go to original source... Go to PubMed...
  43. The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
  44. Vítovec J, Špinar J. Betablokátory v léčbě chronického srdečního selhání. Vnitř Lék 2000;46:161-5. Go to PubMed...
  45. Vítovec J, Špinar J. Diuretika u srdečního selhání. Kapit Kardiol 2002;4:90-2.
  46. Vítovec J, Špinar J. Který betablokátor u srdečního selhání? Studie COMET - dala jasnou odpověd? Cor Vasa 2003;45:527-8.
  47. Vítovec J, Špinar J, a spol. Kardiovaskulární farmakoterapie. 2. vydání. Praha: Grada, 2004.
  48. Widimský J. Betablokátory v léčbě srdečního selhání. JAMA-CS 1999;7:375-7.
  49. Widimský J, a kol. Srdeční selhání. 2. vydání. Praha: Triton, 2003.
  50. Willenheimer R, van Veldhuisen DJ, Silke B, et al. on behalf of the CIBIS III Investigators. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426-35. Go to original source... Go to PubMed...
  51. Wilson Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid Retention After Initiation of Thiazolidinedione Therapy in Diabetic Patients With Established Chronic Heart Failure. JACC 2003;41:1394-8. Go to original source... Go to PubMed...
  52. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with CHF and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81. Go to original source... Go to PubMed...
  53. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl J Med 2000;342:145-53. Go to original source...
  54. Vítovec J, Špinar J. Mohou blokátory receptorů pro angiotenzin II (AIIA) nahradit v léčbě srdečního selhání inhibitory ACE? Cor Vasa 2003;45:169-70.
  55. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial: the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7. Go to original source... Go to PubMed...
  56. Valsartan Heart Failure Trial Investigators, Cohn JN, Tognoni G. A.randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75. Go to original source... Go to PubMed...
  57. Špinar J. Blokátory receptoru 1 pro angiotenzin II v léčbě chronického srdečního selhání. Cor Vasa 2000;42: 117-8.
  58. Goodlin SJ, Hauptman PJ, Arnold R, et al. Consensus statement: palliative and supportive care in advanced heart failure. J Card Fail 2004;10:200-9. Go to original source... Go to PubMed...
  59. Stevenson LW. The Cul-de-Sac at the End of the Road. J Card Fail 2003;9:188-91. Go to original source... Go to PubMed...
  60. Hradec J. Diastolické srdeční selhání. V: Habilitační a inaugurační přednášky na 1. LF UK v Praze 2004. Praha: Galén, 2005:148-54.
  61. Lachmanová J. Očištovací metody krve. Praha: Grada Publishing, 1999:132.
  62. Štejfa M. a spol. Kardiologie. 3. vydání. Praha: Grada, 2007:722.
  63. Táborský M, Kautzner J, Bytešník J, a spol. Zásady pro implantace kardiostimulátorů, implantabilních kardioverterů-defibrilátorů a srdeční resynchronizační léčbu (2005). Supplementum Cor Vasa 2005;47(9):59-68.




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.